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Background: Regular reformulation of currently available vaccines is necessary due to the unpredictable variability
of influenza viruses. Therefore, vaccine based on a highly conserved antigen with capability of induction of effective
immune responses could be a potential solution. Influenza matrix protein-2 (M2) is highly conserved across
influenza subtypes and a promising candidate for a broadly protective influenza vaccine. For the enhancement of
broad protection, four tandem copies of consensus M2 gene containing extracellular (ED) and cytoplasmic (CD)
without the trans-membrane domain (TM) reconstituted from H1N1, H5N1 and H9N2 influenza viruses were linked
and named as 4sM2. The construct was effectively expressed in Escherichia coli, purified and proteins were used to
immunize BALB/c mice. Humoral and cell-mediated immune responses were investigated following administration.
Results: Mice were intramuscularly immunized with 4sM2 protein 2 times at 2 weeks interval. Two weeks after the
last immunization, first humoral and cell mediated immune response specific to sM2 protein were evaluated and
the mice were challenged with a lethal dose (10MLD50) of divergent subtypes A/EM/Korea/W149/06(H5N1),
A/PR/8/34(H1N1), A/Aquatic bird/Korea/W81/2005(H5N2), A/Aquatic bird/Korea/W44/2005(H7N3), and A/Chicken/
Korea/116/2004(H9N2) viruses. The efficacy of 4sM2 was evaluated by determining survival rates, body weights and
residual lung viral titers. Our studies demonstrate that the survival of mice immunized with 4sM2 was significantly
higher (80–100% survival) than that of unimmunized mice (0% survival). We also examined the long lasting
protection against heterosubtype H5N2 virus and found that mice vaccinated with 4sM2 displayed 80% of
protection even after 6 months of final vaccination.
Conclusion: Taken together, these results suggest that prokaryotic expressed multimeric sM2 protein achieved
cross protection against lethal infection of divergent influenza subtypes which are lasting for the long time.
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Influenza A virus, one of the most important pathogen,
causes perennial epidemics and occasional pandemics with
a huge impact on global health and economy. As a zoo-
notic agent it has potential to cause diseases not only to
the poultry industry, but also to the humans and many
species of mammals [1]. Among the two strategies; pre-
vention and therapeutic, prevention being the preferred* Correspondence: jongsool@cnu.ac.kr; cjkim@cnu.ac.kr
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article, unless otherwise stated.option to combat the influenza infection [2]. Thus, several
kinds of influenza vaccines are developed, such as inacti-
vated whole virus vaccines, split vaccines, subunit vac-
cines, and virus-like particles [3-6]. Among them,
inactivated influenza virus vaccines are the most com-
monly use to prevent influenza-associated illness [7].
Current inactivated vaccines are formulated as a trivalent
blend based on known protective surface antigen
hemagglutinin (HA) and neuraminidase (NA) and are de-
signed by predicting the forth coming virus strains, which
requires reformulation regularly. However, production of
an egg-based trivalent vaccine is time consuming andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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situation [8]. Moreover, current strategies using inacti-
vated whole virus vaccines face an annual problem of HA
and NA antigenic mismatch with circulating influenza vi-
ruses due to repeated antigenic drifting [9]. Therefore,
vaccination strategies for broad protectivity against unpre-
dictable influenza viruses need to be developed.
Several approaches are being investigated to develop
broadly protective vaccines and focus mainly on the con-
served region of the viral matrix protein-2 (M2) and HA
proteins of influenza A virus [10]. Compared with HA,
M2 is highly conserved among and within different sub-
types (Table 1), and is therefore an attractive target for de-
veloping a broadly protective vaccine. In particular, the
extracellular domain of M2 is considered an appropriate
target for a broad spectrum influenza vaccine [11]. The ef-
ficacies of different forms of M2-based vaccines have been
studied and found that mice immunization with M2 can
protect against influenza virus lethal infection [12-14].
However, the protection level was not so significant due to
small size and poor immunogenicity of the M2e peptide.
Therefore, focus has shifted to the M2 fusion construct
using a variety of carrier molecules like M2 peptide-
carrier conjugates, baculovirus-expressed M2, M2 fusion
proteins, multiple antigenic peptides, and M2 DNA vac-
cine [14-18]. It has been reported that multimeric form
of the M2 fusion protein, such as TLR5 ligand flagellin
fused to four tandem copies of M2 induced antibody can
protects a lethal challenge of influenza virus in BALB/c
mice [13]. Subsequently, these studies have shown that
immunization with M2 or a multimeric form of M2
based vaccine with or without a carrier can protect hom-
ologous or heterosubtypic influenza virus infections.
However, the longevity and breadth of cross protectivities
of M2 are not well studied.
Therefore, in this study, a construct named 4sM2
using four tandem copies of consensus sM2 gene de-
rived from the analysis of sequences of H1N1, H5N1
and H9N2 influenza viruses without its trans-membrane
domain for the induction of broad protection against di-
vergent influenza virus subtypes were developed. The
construct was expressed in E. coli and potency of theTable 1 Comparison of sM2 sequence among vaccine and cha




A/Puerto Rico/8/34 H1N1 MSLLTEVETPIRN
A/Aquaticbird/Korea/W44/2005 H7N3 MSLLTEVETPTR
A/Chicken/Korea/116/2004 H9N2 MSLLTEVETPTR
The amino acids differ from consensus sequence are in bold and underlined.produced immunogen was evaluated in mouse model
against lethal doses of mouse adapted influenza A vi-
ruses. In addition, the longevity of the immune re-
sponses and breadth of cross protection were examined.
Results
Confirmation of target protein 4sM2
For the expression of target proteins with his-tag fusion
at the N-term, monomer or multimer consensus sM2
plasmids (sM2 and 4sM2, respectively) were constructed
into pRSET A vector. The recombinant proteins were
expressed mainly as inclusion bodies in E. coli. Refolded
inclusion bodies containing the recombinant proteins
were purified by His-tag affinity chromatography and di-
alyzed using permeable cellulose membrane and con-
firmed by SDS-PAGE and immunoblotting. As shown in
Figure 1B, proteins were electrophoresed on the SDS-
polyacrylamide gel and stained with Coomassie brilliant
blue. After destaining, proteins were observed at the ex-
pected molecular weight of 60 kDa (4sM2, Figure 1B)
and 15 kDa (sM2, data not shown). Additionally, reac-
tions of 4sM2 protein with mouse anti-Histidin (C-term,
Figure 1C) and rabbit anti-M2 antibodies (Figure 1D)
were confirmed by immunoblotting. With Coomassie
staining and immunoblotting, no other proteins were
observed around the expected band which indicate,
there were no conformational changes of proteins after
refolding from inclusion bodies.
M2 specific antibody responses to the 4sM2 protein in
mice
Upon confirmation of protein expression and subse-
quent purification, groups of mice were immunized
intramuscularly (i.m.) with 30 μg of 4sM2 protein at
day’s 0 and 14, and sera were collected at day’s -1, 7, and
21 to assess the antibody titer. Serum antibodies were
measured by ELISA using the sM2 protein (Figure 2A),
M2 peptide (Figure 2B) or inactivated purified virions as
a coating antigen. The levels of serum IgG absorbance
increased around 10 fold after the second application of
4sM2 protein compared with those observed before
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Figure 1 Construction of plasmid analysis of recombinant proteins and mouse vaccination schedule. (A) The consensus sM2 genes were
cloned into pRSET A vector. (B) Purified 4sM2 protein from a prokaryotic expression system was confirmed by Coomassie Brilliant Blue staining
and was detected at a molecular weight of 60 kDa. 4sM2 protein expression was verified by Western blot analysis using (C) anti 6 × His
antibodies and (D) antiM2 antibodies. (E) Mice were grouped as shown in Table 2 and all groups were intramuscularly administered twice every
other week. Sera were collected before the first administration and 1 week after each vaccination. Spleens were excised from three mice in each
group of one set 10 days after last immunization. All mice were challenged with a lethal dose of HPAI viruses intranasally and monitored for 13
days at 2 or 24 weeks after the last immunization. At 3 and 5 dpi, lungs were excised from three mice in each group to check the virus titer. Mice
from one set were sacrificed for lung histopathology at 5 dpi. Abbreviations: 4sM2, recombinant multimeric sM2 protein; NC, negative control;
M, protein marker; CB, Coomassie Brilliant Blue.
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showed significant level of antibodies cross reactivities
to influenza subtypes H5N1, H5N2 and H9N2 viruses.
Importantly 4sM2 immune sera also showed significant
levels of cross reactivities to H1N1 and H7N3 subtypes
which contains sM2 sequences of 8 and 2 amino acid
mismatches respectively (Table 1). Control group of
mice that were immunized with 0.85% saline (NC) did
not show any responses against protein, peptide or inac-
tivated whole viruses. Therefore this result suggests that4sM2 is capable to induce antibody which is cross react-
ive to different subtypes of influenza virus.
M2 specific IgG1 and IgG2a were also tested and
found that both IgG1 and IgG2a increased significantly
compare to negative control (NC) after the booster
immunization (Figure 2C), and IgG2a was predominant
than IgG1. These results suggest that the 4sM2 recom-
binant protein is strongly immunogenic and is also cap-
able of producing both Th1 and Th2 inducing M2














































































































































































































































Figure 2 Detection of sM2-specific humoral and cell mediated immune responses. Sera were collected at days 0 (pre-immune), 7 (first
immunization) and 21 (second immunization) of immunization with the 4sM2 recombinant protein. The absorbance of antibody was detected by
indirect ELISA. (A) Detection of serum IgG using the sM2 protein as coating antigen. (B) Detection of serum IgG using the M2 peptide as coating
antigen. (C) Detection of serum IgG1 and IgG2a antibody responses in mouse sera. (D) Detection of serum IgG using the whole inactivated virus as
coating antigen. Splenocytes were harvested 10 days after the last immunization. Cells were re-stimulated in vitro with the sM2 protein or M2 peptide
and cytokine forming cell spots were determined by ELISPOT assay. IFN-γ and IL-4 spot-forming cells per 5 × 105 splenocytes were determined. (E)
Splenocytes producing IFN-γ stimulated with the sM2 protein and M2 peptide. (F) Splenocytes producing IL-4 stimulated with sM2 protein and M2
peptide. Bars denote mean ± standard deviations. Comparison of groups were analyzed by Student’s t-test and ANOVA; the differences were statistically
significant (* P < 0.05). Abbreviations: 4sM2, recombinant multimeric sM2 protein; NC, negative control; PC, positive control.
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To investigate the broad protective immune mechanism,
4sM2 induced IFN-γ and IL-4 secreting cells in the
spleen were determined by ELISPOT. Cells were col-
lected 10 days after the boost immunization and stimu-
lated with sM2 protein or M2 peptide. Significant
numbers of IFN-γ secreting cells were observed in the
spleen following stimulation with both the sM2 protein
(Figure 2E, left) and M2 peptide (Figure 2E, right). We
also observed a detectable level of IL-4 secreting spleno-
cytes following stimulation with both the sM2 protein
(Figure 2F, left) and the M2 peptide (Figure 2F, right).
Mock (un-immunized) mice showed a background level
of spot for both the sM2 protein and M2 peptide stimu-
lation. These findings indicate that four tandem copies
of consensus sM2 can induce M2-specific IFN-γ and IL-
4 secreting T cell responses, which may contribute to
the protective immunity.
Protective efficacy of 4sM2 vaccine against divergent
influenza virus subtypes
The efficacies of the 4sM2 vaccine against the divergent
influenza virus subtypes were investigated. Mice wereimmunized i.m. twice at 2 weeks interval. Two weeks
after the final immunization, mice were challenged intra-
nasally (i.n.) with the 10MLD50 of A/EM/Korea/W149/
06(H5N1) influenza subtype that contains 2 mismatched
amino acids against the sM2 consensus sequence
(Table 1). Protective efficacy and morbidity (measured
by survival rates and weight losses, respectively) were
monitored every other day for 13 days post-infection
(dpi); mice were euthanized and considered dead if the
original body weight is reduced by >25%. As shown in
Figure 3A, immunized mice lost 5–10% of their body
weight but conferred 100% survival by 13 dpi after lethal
challenge of H5N1 virus (Figure 3A). In contrast, re-
markable losses of body weight were observed in unim-
munized mice and none of them survived due to lethal
infection of H5N1 virus (Figure 3A, bottom).
Next the protection efficiency of 4sM2 vaccine against
A/PR/8/34(H1N1) subtype of influenza virus that con-
tains 8 mismatched with sM2 consensus sequence was
evaluated. Set of immunized mice were challenged with
10MLD50 of the H1N1 virus and protection efficacy
were measured as before. Unimmunized mice lost >25%
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Figure 3 Protective against divergent influenza virus subtypes. Five weeks-old female BALB/c mice were immunized twice with 30 μg of 4sM2
protein or 0.85% saline via i.m. Mice were infected intranasally with 10 times the 50% mouse lethal dose (MLD50) of mouse-adapted influenza virus
subtypes (A) A/EM/Korea/W149/06(H5N1), (B) A/PR/8/34(H1N1), (C) A/Aquatic bird/Korea/W81/2005(H5N2) respectively, (D) A/Aquatic bird/Korea/
W44/2005(H7N3) and (E) A/Chicken/Korea/116/2004(H9N2) at 14 days after the final immunization Variations in body weight from the initial mouse
body weight and percent survival were recorded until 13 dpi. The results are expressed as the mean ± standard deviations for the group.
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and 80% were survived (Figure 3B). Another set of vacci-
nated mice were infected with A/Aquatic bird/Korea/
W81/2005(H5N2) influenza virus to better understand the
degree of cross protection by 4sM2 vaccine. The sM2 se-
quence of H5N2 contains 1 mismatched against sM2 con-
sensus sequence. All mice in the control group became
severely ill (lost weight >25%) and eventually died by 9
dpi. In contrast, the 4sM2 immunized group experienced
19% loss in body weight within 3 to 9 dpi, but started to
recover thereafter; 100% of the vaccinated mice were sur-
vived the H5N2 virus infection (Figure 3C). The breadths
of cross protection of the 4sM2 vaccine against divergent
influenza subtypes were further examined. For this, 2 sets
of immunized mice were challenged with A/Aquaticbird/
Korea/W44/2005(H7N3) or A/Chicken/Korea/116/2004
(H9N2) that contain 2 and 3 amino acid mismatched with
sM2 consensus sequence respectively. In both cases unim-
munized mice were severely ill (lost weight >25%) and
died by 9 to 11 dpi. Although, mice immunized with
4sM2 showed little body weight loss, but recovered grad-
ually and finally 60% and 80% survived the H7N3 and
H9N2 virus challenges respectively (Figure 3D and E).
Taken together, the results showed that immune responses
induced by highly conserved 4sM2 vaccine conferred the
protection against divergent subtypes of influenza virus le-
thal infection either it is complete or partial.
Lung virus titers and histopathology
Virus titers in the lungs of challenged mice were mea-
sured to estimate the virus clearance at 3 and 5 dpi. The4sM2 immunized mice had significantly reduced lung
virus titers at day 3 and had completely cleared the infec-
tion by day 5 in case of H5N1 virus challenge (Figure 4A).
Similarly, the immunized mice elicited significant reduc-
tion of lung virus titers in compare to unimmunized mice
by 5 dpi in case of H1N1 and H5N2 influenza virus
(Figure 4B and 4C). The clearances of viruses from the
lung after challenge with H7N3 (Figure 4D) and H9N2
(Figure 4E) subtypes were also assessed. Both immunized
and unimmunized mice showed high lung virus titers at 3
dpi. In contrast, virus titers decreased significantly in im-
munized group at 5 dpi which correlate the survival result
of both H7N3 and H9N2 lethal infection. A histopatho-
logical examination was also performed to correlate the
virus clearance in the lungs. Representative lungs samples
were collected after challenge with H5N2 virus and
process to examine under light microscope. As shown in
Figure 4F, clear signs of profound pulmonary inflamma-
tions were observed in unimmunized mice lung, whereas
the mice immunized with 4sM2 showed no significant
pulmonary inflammation (Figure 4F). These results dem-
onstrate that consensus 4sM2 protein vaccine induced im-
mune responses strong enough to completely clear the
H5N1 and H5N2 subtypes and significantly reduce the
virus titers of H1N1, H7N3 and H9N2 influenza subtypes
in vivo.
The 4sM2 vaccination induces long lasting cross
protection
Duration of protection ability is an important criterion
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Figure 4 Lung virus titers and histopathology. Virus titers in lungs tissues were determined by TCID50 in the MDCK cell line at 3 and 5 dpi
with (A) A/EM/Korea/W149/06(H5N1), (B) A/PR/8/34(H1N1), (C) A/Aquatic bird/Korea/W81/2005(H5N2) respectively, (D) A/Aquaticbird/Korea/W44/
2005(H7N3) and (E) A/Chicken/Korea/116/2004(H9N2) influenza subtypes. Bars denote mean ± standard deviations. Comparisons of groups were
analyzed by Student’s t-test and ANOVA; the differences were statistically significant (P < 0.05). (F) Lungs of the vaccinated mice show clear alveoli
without inflammatory cell infiltration as opposed to the lungs of control mice which revealed the features of severe pneumonitis. Tissues were
observed by light microscope with 200× magnification.
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were immunized according to the schedule mentioned
previously, and sera were collected at -1 (pre), 21 (2nd),
and 180 days after vaccination. Consistent levels of
serum IgG specific to sM2 were determined even at 180
days after the final vaccination (Figure 5A). Mice were
then challenged with A/Aquatic bird/Korea/W81/2005
(H5N2) influenza subtype; morbidity and mortality were
checked until 13 dpi. The unimmunized mice showed
>25% body weight loss (Figure 5B) and all mice died at 9
dpi whereas the immunized mice survived 80% with
negligible body weight loss which was recovered by 13
dpi (Figure 5C). This result demonstrates that 4sM2 vac-
cine conferred protection even after 6 months of final
vaccination against heterosubtype lethal infection.
Discussion
M2 is one of the most promising conserved antigens,
produced by translation from a spliced mRNA derivedfrom influenza gene segment 7, which also cedes for
matrix protein M1. It is a type III transmembrane pro-
tein in the form of a tetramer that functions as a pH-
regulated proton channel and sparsely present on virus
particles but is abundant on the surface of virus-infected
cells [19]. Various M2e sequences of M2 constructs have
been expressed and used as vaccines. In previous study,
it has shown that H5 derived vaccines may also protect
circulating H1N1 and H3N2 subtypes. Nevertheless, M2
vaccines might also protect against an unexpected sub-
types that could cause a pandemic though protection
across substantial divergence [16].
Thus, we developed sM2 consensus derived from the
analysis of sequences of H5N1, H1N1 and H9N2 sub-
types in the database. Considering the previous findings
that extracellular domain particularly (aa, 1–13) is highly
conserved among the influenza virus subtypes and rec-
ognized as epitope for the induction of monoclonal anti-














































































Figure 5 Long-lasting protections against the heterosubtype influenza virus. Groups of mice immunized with 30 μg of 4sM2 protein twice
at 2 week interval. Control mice were inoculated with 0.85% saline. Sera were collected on days 0, 21, and 180. An ELISA was performed in
triplicate using the coated sM2 protein to confirm long lasting antibody level. Mice were challenged with lethal doses of A/Aquaticbird/Korea/
W81/2005(H5N2) virus (10× MLD50) 6 months after the final immunization. (A) Absorbance of the IgG antibody specific to the sM2 protein. (B)
Percent body weight loss and (C) percent survival, after infection with the influenza virus. Bars denote mean ± standard deviations. Comparisons
of groups were analyzed by Student’s t-test and ANOVA; the differences were statistically significant (P < 0.05). Abbreviations: 4sM2, recombinant
multimeric sM2 protein; NC, negative control.
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were used. For the possible homology among other sub-
types we changed at the position of 14 (E-G), 18 (R-K)
and 24 (E-D) and kept unchanged the conserved epitope
(aa, 1–13). As shown in sequence alignment, sM2 of
consensus sequence has 1–8 mismatches among the
subtypes used in this study (Table 1). The developed
sM2 plasmids (monomeric and multimeric) were suc-
cessfully expressed in E. coli and subsequently purified
on Ni-NTA agarose. The purified proteins were formu-
lated in PBS buffer and tested for its ability to stimulate
the immune response and the level of protection against
lethal challenge of divergent influenza subtypes.
The M2 specific antibody cannot contribute directly to
neutralize virus in vitro, the antiviral effect of an M2-
based vaccine may be exhibited by antibodies to the M2
antigen through antibody-dependent cell-mediated cyto-
toxicity [11]. Therefore, induction of the M2 specific
antibody level was investigated after two intramuscular
doses. High level of M2 specific antibody was identified
following immunization with Freund’s adjuvant, which is
the most commonly used adjuvant in animal experiment
model (Figure 2A and B). Our study also demonstratedthat 4sM2 vaccination induces antibodies reacted to
purified virions regardless of HA subtypes (Figure 2D).
For investigating the possible mechanism of protection
associated with sM2 based vaccine, the isotyping of IgG
were performed and found both IgG1 and IgG2a were
predominantly induced by 4sM2 vaccinated mice which
may contributed to reduction of lung virus titers. Previ-
ous study showed that recombinant HA of influenza
virus (rHA) with nanoparticles (NP) could induce IgG1
and IgG2a as high as half dose of inactivated virus vac-
cine (IV) without adjuvant. IgG2a was dominant in case
of both rHA and IV when administered with NP adju-
vant [23]. On the contrary, Zhao et al. demonstrated
that M2e peptide with ASP-1 adjuvant could not in-
crease the Th1 (IgG2a) immune response compare to
Th2 (IgG1) and suggesting that the selection of an ap-
propriate adjuvant and its unique ability to stimulate
functional immune response is critical to the success of
M2e based vaccine [24]. However, induction of M2 spe-
cific IgG2a antibodies contributes the clearance of vi-
ruses [18]. Similarly, reduction of virus titers in the
lungs of 4sM2-vaccinated mice after a lethal infection of
divergent influenza subtypes (Figure 4A, B, C, D and E)
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the clearance of virus. In addition, the 4sM2 vaccination
also can reduce the severity of lung damage by inhibiting
viral replication and accumulation of inflammatory cells
in lung alveolar tissues (Figure 4F).
Since the first report of cross protection by Slepushkin
et al. [25], numerous studies have done with different
approaches to provide cross protection immunity using
the conserved M2 sequence. A number of Studies
already been conducted focusing on the monomeric
M2e proteins expressed in E. coli, M2 DNA vaccine, M2
peptide, M2 protein conjugates with different molecules
and M2 VLP [14-17]. The routes of administration and
the cross protection also been investigated [10,18]. How-
ever, for the increasing protection levels, focus goes to
multimeric form of M2 protein and peptide. Study
showed that 4 ×M2e conjugated Mycobacterium tuber-
culosis HSP70 (mHSP70) fusion protein provided full
protection against lethal dose of mouse-adapted H1N1,
H3N2, or H9N2 influenza A isolates [26]. A Similar
study by Alvarez et al. [27] demonstrated that four cop-
ies of the M2e peptide to the BLS molecule (Brucella
abortus derived antigen) were capable to induce 100%
protection from viral challenge in BALB/c mice. Re-
cently, Kim et al. [28] reported on cross-protection re-
gardless of influenza virus subtypes by tandem repeat of
M2e (M2e5×) expressing virus like particles. The multi-
meric M2e-based vaccines reported have shown to be ef-
fective for cross protection when conjugated to other
molecules or delivered as a whole virus and mainly
based on conserved epitope of M2 ectodomain (M2e)
which is small in size and low immunogenic. However,
in the present study, we used sM2 constituted both ecto
and cytoplasmic domain without the transmembrane do-
main for the enhancement immunogenicity and breadth
of protection, which is utmost important to protect un-
expected outbreak of influenza infection.
The cellular immune response plays an important role
in vaccination. Previous studies have reported on anti-
bodies and cell-mediated cytotoxicity specific to the M2
antigen and their anti-viral activity [29] and E. coli
expressed monomeric M2, three copies of M2 fused with
ASP-1 significantly induce anti-M2 Th1 and Th2 associ-
ated antibodies [24]. Wu et al. [30] reported that nucleo-
tide based CpG-ODN adjuvant with M2 peptide
significantly increased M2-specific IgG2a and IFN-γ se-
creting lymphocytes. In agreement with those findings,
we examined the Th1-type (IFN-γ) and Th2-type (IL-4)
cytokine responses by ELISPOT assay. Heightened levels
of IFN-γ were detected in response to stimulation of
both the sM2 protein and M2 peptide in mice immu-
nized with the 4sM2 protein but not in non-immunized
mice (Figure 2E). Similarly, we observed substantially
high levels of IL-4 in immunized mice upon stimulationwith the sM2 protein and M2 peptide (Figure 2F). To-
gether, these results indicate that four tandem copies of
sM2 with Freud’s adjuvant induced a cellular immune
response that may contributed to protecting mice from
widely divergent influenza subtypes from both phylogen-
etic group 1 (H1, H5, H9) and group 2 (H7) [31].
Our study revealed that reconstituted 4sM2 protein
which from E. coli induced long lasting immunity and
conferred protection against a heterosubtype influenza
virus lethal infection even at 6 months after final vaccin-
ation (Figure 5B and C). Our findings supported by the
previous observation that M2 VLP confers long-term
immunity and cross protection [18]. Also, a report by
Price et al. showed long lived NP/M2 specific IgG and
IgA antibodies in sera and mucosal sites [32]. In ag-
reement with these findings, we found that the sM2
specific antibody-mediated immunity was long lived
(Figure 5A), which is important for any successful
vaccine.
Conclusion
Influenza A viruses are responsible for three major pan-
demics in the twentieth century and occasionally out-
breaks in various hosts such as, humans, avian species,
and some types of mammals. It has one of the highest in-
fection rates of all human viruses which can infect people
of all ages [33]. Efforts to develop effective influenza vac-
cines are repeatedly challenged due to the genetic in-
stability of HA and NA [34]. A vaccine consisting of a
genetically conserved influenza antigen would provide a
second layer of protection against multiple strains and
could offer the promise of influenza vaccination in the
developing world where the current seasonal strategy is
not practical [35]. Therefore, the development of univer-
sal influenza vaccines against various subtypes is badly
needed and should be studied continuously. In this study,
the efficacy of reconstituted multimeric sM2 proteins
(4sM2) which expressed in E. coli in providing cross-
protection against lethal infection of divergent influenza
subtypes were demonstrated. We showed evidence that
vaccine containing multimeric sM2 which in this case
4sM2 proteins could be potential candidate for inducing
cross-protection, as shown against A/EM/Korea/W149/
06(H5N1), A/PR/8/34(H1N1), A/Aquatic bird/Korea/W81/
2005(H5N2), A/Aquatic bird/Korea/W44/2005(H7N3), and
A/Chicken/Korea/116/2004(H9N2) influenza subtypes.
The cross reactivity and protective efficacy suggests that
4sM2 protein, could potentially promote protection
against influenza subtypes. Overall, our results demon-
strate that four tandem copies of consensus sM2 conferred
broad protective immune responses against divergent in-
fluenza subtypes in a mouse model, suggesting that sM2
could be used to produce a broadly protective influenza
vaccine.
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Construction of recombinant plasmid with four copies of
the sM2 gene
A gene encoding the consensus sM2 containing residues
of extracellular and cytoplasmic domain without the trans-
membrane domain from the analysis of sequences of
H5N1, H1N1 and H9N2 subtypes in the database was
chemically synthesized (Figure 1A). Plasmid sM2 and
4sM2 were constructed by cloning as described previously
[36]. The sM2 gene was modified by adding a Nhe I site at
the 5′ terminal and BamH I and Hind III sites as well as
the termination codons TAA and TGA at the 3′ terminal
for cloning into the pRSET A vector. The polymerase
chain reaction (PCR) was employed to amplify the gene
using the primer pair 5′-CTA GCT AGC ATG TCA TTA
TTA ACA-3′ (sense 1), 5′-GAA GAT CTA TGT CAT
TAT TAA CA- 3′ (sense 2) and 5′-AAG CTT TTA TCA
GGA TCC ACC TGA ACC ACC TGA ACC ACC TGA
ACC ACC TTC AAG TTC-3′ (anti sense). Two different
primer senses were simultaneously used during this multi-
cloning process. The sM2 (sense 1) was ligated with
pRSET A using a CoreBio 96 plus thermocycler (CoreBio
L&B, Seoul, Korea), whereas sM2 (sense 2) was ligated
into the T Easy Vector (Invitrogen, Seoul, Korea). Each
plasmid was linearized by RE digestion using BamH I,
Hind III for the pRSET A vector and Bgl II, Hind III for
the T Easy Vector at 37°C for 2 h and purified by phenol/
chloroform/ isoamylalcohol treatment. The linearized
plasmids were electrophoresed on a 0.9% agarose gel and
recovered using a QIAquick Gel Extraction kit (Qiagen,
Hilden, Germany) following the manufacturer’s instruc-
tions. The pRSET A vector and sM2 insert (sense 2) were
ligated with T4 ligase (TaKaRa Bio, Seoul, Korea) at 16°C
for 4 h. Sense 1 for sM2 was fused to sense 2 to produce
2sM2. Consequently, 4sM2 was produced by combining
2sM2 (sense 1) to 2sM2 (sense 2). The ligated products
were transformed into E. coli JM83 competent cells using
an electroporation method described previously. The re-
combinant plasmids were recovered by plasmid DNA ex-
traction following the manufacturer’s instructions using
Accuprep Plasmid Mini-prep (Bioneer, Daejeon, Korea).
The profiles of the recombinant plasmids were confirmed
by restriction endonuclease digestion and DNA sequen-
cing (Solgent, Seoul, Korea).
Expression of 4sM2 proteins in E. coli
Proteins sM2 and 4sM2 were generated using an E. coli
expression system as described previously [37,38]. Briefly,
recombinant plasmids were introduced into the E. coli
BL21 (DE3) strain using the heat shock method of trans-
formation. A colony was seeded in 5 ml LB broth supp-
lemented with 100 μg/ml ampicillin and 35 μg/ml
chloramphenicol and grown at 37°C with shaking. The
overnight culture was transferred to 800 ml fresh LBmedium and cultured at 37°C with 200 rpm shaking.
When the culture reached an optical density (OD) of 600
nm (OD600) at 0.6, expression of the target proteins were
induced by adding 2 mM isopropyl-β-D-thiogalactopyran-
oside (99% purity; Bio Basic, Ontario, Canada) and incu-
bating for another 12 h at 30°C. Cultures were then
harvested by centrifugation at 6,000 × g for 20 min at 4°C.
The cell pellets were stored at -20°C overnight.Isolation, solubilization and refolding of protein from
inclusion bodies (IBs)
For the isolation of inclusion bodies (IBs), cell pellets were
thawed in ice and re-suspended in 20 ml cold buffer con-
taining 20 mM Tris-HCL, 0.5 M NaCl, 10% glycerol and
protease inhibitor (1 mM phenyl methyl sulfonyl fluoride,
Sigma-Aldrich, Seoul, Korea). Bacterial lyses was per-
formed by sonication for 3 min with an interval of 2 s
pulses and 1 s resting at 25% amplitude and centrifuged
(12,000 × g, 20 min) at 4°C. Supernatant was removed and
remaining pellet retained as IBs. The collected pellet was
resuspended with denaturing buffer (20 mM Tris-HCl, 0.5
M NaCl, 10% glycerol and 6 M urea) followed by sonic-
ation for 1 min and centrifuged as before. Debris super-
natant was discarded; remaining pellet was resuspended
with denaturing buffer II (20 mM Tris-HCl, 0.5 M NaCl, 8
M urea, pH 8.0) and kept in 4°C with shaking overnight.
The pellet was sonicated and centrifuged as before. Super-
natant was separated as rescued protein from IBs, which is
ready for purification [39].Purification, dialysis and confirmation of 4sM2 specific
protein
The target proteins were purified by His-tag affinity
chromatography (Qiagen, USA), dialyzed using a perme-
able cellulose membrane (molecular cut-off: 12–14 kDa,
Spectrum Laboratories, East Tamaki, Auckland, USA)
for 24 h at 4°C. The dialyzed target proteins were quan-
tified using the Bradford assays (Bio-Rad, Hercules, CA,
USA) and confirmed by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). For im-
mune detection of protein, the membranes were probed
with mouse anti-histidine antibodies (1:500, Invitrogen,
Carlsbad, CA, USA) and rabbit anti-M2 antibodies
(1:1000). Rabbit anti-M2 antibody used in this experi-
ment was generated by i.m. inoculation of KLH conju-
gated M2 peptide to the rabbit, two times of 2 weeks
interval. Membranes were reacted with a 1:1000 dilution
of anti-mouse or anti-rabbit IgG HRP. Finally, the target
proteins were detected using the WEST-ZOL plus West-
ern Blot Detection System (iNtRON Biotechnology,
Gyeonggi-do, South Korea) and visualized by enhanced
chemiluminescence (ECL). The purified proteins were
used as a vaccine [23].
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Preliminary experiment was conducted to determine the
doses and efficacy of sM2 and 4sM2 protein on influenza
virus infection. Mice vaccinated with sM2 (10 μg and 30
μg) showed 40% and 60% survival respectively while the
mice vaccinated with 4sM2 (10 μg) registered 60% survival
and the 4sM2 (30 μg) showed 100% survival against lethal
infection of H5N1 (data not shown). In this study, mono-
meric sM2 protein was used as coating antigen for ELISA
and stimulator in ELISPOT, multimeric 4sM2 protein
used for vaccine study. For this, a total of 138 female
BALB/c mice (5 weeks old) were purchased from Samtako
(Seoul, Korea) and acclimated for 7 days at room
temperature prior to use. Mice were divided into six ex-
perimental sets (Table 2). Four sets contained two groups
of 11 mice each. One set had two groups of 17 (6 mice for
lung histopathology at 3 and 5 dpi) mice each. The
remaining sets had two groups containing eight mice each
(for the long lasting and CTL response experiment). Mice
were vaccinated i.m. with 30 μg of 4sM2 protein or 0.85%
saline at 2 weeks interval as illustrated in Figure 1D. Mice
inoculated with 0.85% saline considered as a negative con-
trol (NC). The first injection included Freund’s complete
adjuvant, and 2 weeks later mice were given a boost with
4sM2 or 0.85% saline in Freund’s incomplete adjuvant.
The highly pathogenic (HPAI) A/EM/Korea/W149/06
(H5N1), A/Puerto Rico/8/34(H1N1), A/Aquatic bird
/Korea/W81/2005(H5N2), A/Aquatic bird/Korea/W44/
2005(H7N3) and A/Chicken/Korea/116/2004(H9N2) in-
fluenza subtypes used in this study, were obtained from
the virus collection at the College of Medicine and Med-
ical Research Institute, Chungbuk National University,
Cheongju, Republic of Korea. All viruses were propa-
gated in allantoic fluid from 10-day-old chicken embryos.
Sample collection
Blood were collected to analyze serum antibody levels at
0, 7, 21, and 180 days after vaccination. Blood wereTable 2 The design groups for mouse experiment




(3 and 5 dp
4 0.85%
saline
Freund’s i.m. 11 3 for
each time




Freund’s 17 3 for
each time





4sM2 Freund’s 8 -collected from the retro-orbital plexus, incubated at
room temperature for 30 min; sera were separated by
centrifugation (12,000 × g, 5 min) and stored at -20°C
until analysis. Ether narcosis-anesthetized mice were
bled from the heart with a syringe, dissected to expose
the thoracic cavity, and the lungs were collected asep-
tically to determine lung virus titer and lung histo-
pathology. Samples for the lung virus titer were stored
at -70°C, and the histopathology samples were fixed in
10% formalin until analysis [36,40].
Evaluation of antibody
The antibody level specific to sM2 was evaluated by
ELISA as described previously [23,41]. Briefly, 96-well
immunosorbent plates (Nunc-Immuno Plate MaxiSorp;
Nunc Life Technologies, Basel, Switzerland) were sensi-
tized with 3 μg/ml of sM2 protein, M2 peptide or inacti-
vated purified virions for 12 h at 4°C then washed three
times with PBS (pH 7.4) containing 0.05% Tween 20
(PBS-T). The wells were blocked with 300 μl of 10%
skim milk in PBS for 2 h at room temperature followed
by washing again with PBS-T. Sera were diluted 1: 500
for protein and peptide and 1:100 for virus coated plates,
added in triplicate, and incubated for 2 h at 37°C. Fol-
lowing another round of washing rabbit anti-mouse IgG
HRP antibody (Sigma, Seoul, Korea) was added to each
well (1:1000), and incubated for an additional 2 h at
37°C. Substrate solutions containing tetramethylbenzi-
dine and H2O2 were added after final washing. The reac-
tion performed at room temperature and terminated
immediately with stop solution (2 N H2SO4). Optical
density was measured at 450nm using an ELISA auto
reader (Molecular Devices, Sunnyvale, CA, USA).
IgG isotyping was performed under the same condi-
tions described for the IgG ELISA except for the second-
ary antibody. After the primary antibody reaction, the
ELISA plates were incubated with 1000-fold diluted




(3 and 5 dpi)
ELISPOT Challenge
viruses
5 - - H5N1 H1N1
H7N3 H9N2
5 - -
5 3 + 3 - H5N2
5 3 + 3 -
5 (long lasting) - 3 H5N2
5 (long lasting) - 3
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steps were performed as described for the IgG ELISA.
Enzyme-linked immunosorbant spot (ELISPOT) assay
Cytokine ELISPOTs were developed and counted as de-
scribed previously to detect and compare the T-cell re-
sponse to the 4sM2 protein [42,43]. Briefly, BD ELISPOT
96-well plates were coated with anti-mouse interferon
IFN-γ or interleukin IL-4 capture antibodies in 100 μl
PBS/well and incubated at 4°C overnight. The plates were
blocked with complete RPMI 1640 medium containing
10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA),
and incubated in RT for 2 h. Freshly isolated splenocytes
were added at 5 × 104 cells/well in media containing the
sM2 protein (1 μg/well) or M2 peptide (1 μg/well) or only
medium (negative control), or 5 μg/ml phytohemagglu-
tinin (positive control, Invitrogen, Carlsbad, CA, USA).
Plates were incubated for 48 h at 37°C in 5% CO2. After
discarding the cells, the plates were treated sequentially
with biotinylated anti-mouse IFN-γ and IL-4 antibodies,
streptavidin-HRP, and substrate solution. Finally, the
plates were washed with deionized water and dried for at
least 2 h in the dark. Spots were counted automatically
using an Immuno Scan Entry analyzer (Cellular Technol-
ogy Ltd., Shaker Heights, OH, USA).
Virus challenge
Mice were anesthetized by ether narcosis and infected in-
tranasally with 10MLD50 of challenge viruses in 20 μl
PBS. The MLD50 of A/EM/Korea/W149/06(H5N1), A/
PuertoRico/8/34(H1N1), A/Aquatic bird /Korea/W81/
2005(H5N2), A/Aquatic bird/Korea/W44/2005(H7N3),
and A/Chicken/Korea/116/2004(H9N2) viruses were de-
termined in 8 week old naive BALB/c mice. Lungs were
collected at 3 and 5 dpi to measure lung virus titers and
assess lung histopathology. Remaining mice were moni-
tored for body weight changes and survival. Three mice
from one set were selected at random 10 days after the
final vaccination to analyze the T-cell immune responses.
The remaining mice from the same set were challenged
at 180 days (after final vaccination) for the long lasting
protection assay.
Virus quantification
Lung virus titers were determined as the 50% tissue cul-
ture infectious dose (TCID50) as described previously
[44,45]. Briefly, lung tissues were homogenized in 500 μl
PBS containing antibiotic and antimycotic compounds
(Gibco, Grand Island, NY, USA). The supernatants were
collected after centrifugation (12,000 × g, 15 min) of
mechanically homogenized lung samples. MDCK cells
were inoculated with a 10-fold serial dilution of sample
and incubated at 37°C in a humid atmosphere of 5%
CO2 for 1 h. After 1 h of absorption, media was removedand overlay medium containing L-1-tosylamido-2-phe-
nylethyl chloromethyl ketone (TPCK) trypsin (Thermo
Fisher Scientific, Rockford, USA) was added to the in-
fected cells and incubated for 3 days. Viral cytopathic ef-
fects were observed daily, and titers were determined by
the HA test. For HA, chicken red blood cells (0.5%) were
added to 50 μl of cell supernatant and incubated for 30
min. The virus titer of each sample was expressed as
50% tissue infected doses using the Reed-Muench
method.
Histopathology
Lungs were collected aseptically at 3 and 5 days post in-
fection. Tissues were fixed in 10% formalin solution, em-
bedded in paraffin, sectioned, and stained with eosin.
Tissue sections were examined under a light microscope
to assess the pathological changes [46].
Statistics
Data are presented as means ± standard deviations and
are representative of at least three independent experi-
ments. Differences between groups were analyzed by
analysis of variance (ANOVA) and means were com-
pared by Student’s t-test. P-values less than 0.05 were
regarded as significant.
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